BioNTech and Triastek have entered into a research collaboration and platform technology license agreement to develop RNA therapeutics for oral delivery based on 3D printing technology. The collaboration aims to provide groundbreaking therapies to address unmet medical needs in an easy to administer oral formulation. The partners plan to use Triastek’s knowledge in oral tablet […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!